Methamphetamine Use DisorderEarly Phase 1NCT06899594
Psilocybin for Methamphetamine Addiction
A Early Phase 1 study testing Psilocybin 25 mg in people with Methamphetamine Use Disorder, run by Kevin Murnane at 1 site in United States.
Trial summary
The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Read more about this study
- Who is it for?
- Ages 25 to 65 years
- Conditions the study is for
- Methamphetamine Use Disorder
- What is being tested?
- Psilocybin 25 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 4 Apr 2025to Mar 2027
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 25-65 at time of signing informed consent
- Identification of methamphetamine as drug of choice
- Score of at least 3 on the Severity of Dependence Scale
- Have been at the designated local treatment facility for at least 7 days
- Use of methamphetamine in the month preceding admission to the treatment center
- Desire to cease methamphetamine use as indicated by a goal of complete methamphetamine abstinence on the Thoughts about Abstinence questionnaire
Show all 12Show fewer
- All English speakers, as all neuropsychological tasks will be given in English
- No prior psychedelic use or it will have been at least 3 years since their last use of a psychedelic
- Ability to attend two telehealth and one in person preparatory session appointments to establish comfort, trust and rapport between subjects and the research team and discuss the subjects' goals and aspirations with regard to the psilocybin administration.
- Ability to attend two integration sessions via telehealth and 3 follow-up assessments in person and via telehealth.
- Diagnosis of Stimulant Use Disorder - Amphetamine type on the MINI (Mini International Neuropsychiatric Interview), with no other substance dependence diagnoses other than nicotine or cannabis
- In acute remission from methamphetamine for at least 7 days prior to experimental drug administration as assessed by self-report and confirmed by urine drug screen (UDS) as well as the lack of any acute signs of intoxication on psychoactive drugs other than nicotine
Who cannot join
- Meeting criteria for substance dependence diagnoses other than methamphetamine (except nicotine and cannabis) as assessed by the MINI
- History of Hallucinogen Use Disorder or Hallucinogen Persisting Perceptive Disorder
- Women who are pregnant, plan to become pregnant, or are breast feeding
- Women who do not agree to engage in abstinence or are not using dual contraceptive methods at the time of enrollment and for the study duration
- Current hypertension (exceeding 140 systolic and 90 diastolic at resting as described below) at screening or during vitals taken pre-dosing
- Heart rate of less than 60 bpm and greater than 100 bpm at screening or during vitals taken pre-dosing
Show all 33Show fewer
- QTc of less than 350 msec or more than 460 msec
- History of cardiovascular disease (other than controlled hypertension) or cerebral vascular disease
- Unstable medical or psychiatric conditions or disorders as determined at the discretion of the attending psychiatrist
- Clear diagnosis of schizophrenia or type 1 bipolar disorder (clear from confusion with drug-induced acute states)
- Having current or recent (last 6 months) suicidal ideation, assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
- Subjects currently taking medications on the prohibited medications list or that are unwilling/unable to cease medication
- History of significant brain injury or seizure disorder
- Inability to understand the informed consent, study purpose and procedures, or other study materials involved in the research study
- Those with moderate to severe hepatic impairment, as assessed by laboratory parameters.
- Plans to move away from Shreveport-Bossier area in the next 6 months
- Subjects whose laboratory blood tests demonstrate clinically significant abnormalities. Clinically acceptable ranges listed below:
- Complete Blood Count (CBC) Red Blood Cell Count (RBC): 4.5 - 6.0 million cells/µL
- Hemoglobin (Hb or Hgb):
- For men: 13.8 - 17.2 g/dL
- For women: 12.1 - 15.1 g/dL
- Hematocrit (Hct):
- For men: 38.3% - 48.6%
- For women: 35.5% - 44.9% White Blood Cell Count (WBC): 4,500 - 11,000 cells/µL Platelet Count: 150,000 - 450,000 cells/µL
- Blood Chemistry with Liver Function Tests Alanine Transaminase (ALT): 7 - 56 units/L Aspartate Transaminase (AST): 8 - 48 units/L Bilirubin (Total): 0.2 - 1.2 mg/dL
- Renal Function Tests Blood Urea Nitrogen (BUN): 7 - 20 mg/dL Creatinine: 0.6 - 1.3 mg/dL
- If there are abnormalities, or if the results are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities or deviations from normal to not be clinically significant, or indicative of an unstable medical condition.
- Prohibited Medications If subjects have a history of taking the following medications, they should be discontinued at least 5 half-lives prior to administering psilocybin.
- Medications that antagonize the serotonin 2A receptor
- Medications with serotonergic activity (e.g., SSRIs, SNRIs, efavirenz, lithium)
- Medications that inhibit UGT1A9 or UGT1A10 enzymes
- Monoamine Oxidase Inhibitors (MAOIs)
- Medications that inhibit aldehyde or alcohol dehydrogenase
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
LSU Health Shreveport
Shreveport, Louisiana, 71103
About this study
Official title: A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine
The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and tolerability as rates of retention and challenging experiences, among other factors.
Read the detailed description
This is an open-label pilot study evaluating the feasibility and tolerability of a single 25 mg psilocybin dose in promoting abstinence from methamphetamine. Participants will attend 10 to 12 study visits over a period of up to six months.
Participants will be recruited from a population receiving treatment for methamphetamine dependence at a local residential treatment facility. Recruitment will involve informative presentations to current clients and counselor-facilitated referrals based on provided inclusion criteria. Prescreening will utilize information collected by the treatment center during the client's admission process.
Individuals who meet prescreening criteria will be invited to an in-person screening visit, conducted after obtaining informed consent. The screening visit will include a clinical review, a detailed psychiatric interview, self-report questionnaires, a comprehensive medical history, and safety laboratory testing, including blood draws.
Once eligibility is confirmed, participants will proceed with study enrollment and complete baseline assessments, which will measure substance use, quality of life, and executive function. Three preparatory sessions will follow over a two-week period to establish trust and rapport between participants and session monitors, educate participants on the study protocol, and prepare them for the psilocybin session. Two preparatory sessions may be conducted via telehealth to enhance feasibility, while the third will be conducted in person with both the primary and secondary monitors present. A medical examination will be performed within the week preceding psilocybin administration.
Within a week of the third preparatory session, participants will attend a psilocybin administration session. Participants will arrive at the study location by 9:30 AM and undergo safety screenings, including breathalyzer testing, before psilocybin administration at approximately 10:00 AM. Participants will have been instructed to consume a low-fat breakfast prior to arrival. During the session, cardiovascular measures (e.g., heart rate, blood pressure) will be monitored upon arrival, hourly throughout the session, and as clinically indicated.
The psilocybin session, lasting approximately 6-8 hours, will be monitored by both the primary and secondary session monitors, ensuring that at least one individual is present with the participant at all times. At the conclusion of the session, participants will complete questionnaires assessing their subjective experiences. Participants will then be released into the care of treatment center staff, who will provide emotional support. Participants will also receive contact information for the primary monitor to access support if needed.
Post-session integration will include two telehealth sessions: the first within one day of the psilocybin session and the second approximately 7 days later (±3 days). These sessions will provide opportunities to discuss insights or challenges arising from the psilocybin experience, with an emphasis on promoting adaptive cognitive and behavioral changes.
Follow-up assessments will occur via telehealth at 30 and 60 days post-psilocybin, with an in-person assessment conducted at 120 days. The final visit will include a urine drug screen.
- Conditions
- Methamphetamine Use Disorder
- Being tested
- Psilocybin 25 mg
- Keywords
- Methamphetamine, Psilocybin, Psychedelics, Methamphetamine Use Disorder, Stimulant Use Disorder, Methamphetamine Addiction, Addiction, Substance Use Disorder, Abstinence
- Medical subject headings
- Behavior, Addictive, Substance-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Psilocybin 25 mgDrug
25 mg administered orally (capsules)
| Study group | Role | What they receive |
|---|---|---|
| Psilocybin | Experimental | Participants will be administered 25mg of Psilocybin. Receives: Drug: Psilocybin 25 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Participant retention rate
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant.
Measure:
- Retention rate (percent of scheduled study visits completed by each participant).
Measured: Screening, Visit #1
Participant retention rate
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant.
Measure:
- Retention rate (percent of scheduled study visits completed by each participant).
Measured: Baseline Assessments, Visit #2
Participant retention rate
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant.
Measure:
- Retention rate (percent of scheduled study visits completed by each participant).
Measured: Preparatory Session #1, Visit #3 (on study day (-)14; 14 days prior to dosing)
Participant retention rate
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant.
Measure:
- Retention rate (percent of scheduled study visits completed by each participant).
Measured: Preparatory Session #2, Visit #4 (on study day (-) 7; 7 days prior to dosing)
Participant retention rate
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant.
Measure:
- Retention rate (percent of scheduled study visits completed by each participant).
Measured: Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing)
Participant retention rate
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant.
Measure:
- Retention rate (percent of scheduled study visits completed by each participant).
Measured: Day of drug administration, Visit #6 (on study day 0)
Participant retention rate
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant.
Measure:
- Retention rate (percent of scheduled study visits completed by each participant).
Measured: 1-Day post drug administration integration session, Visit #7
Participant retention rate
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant.
Measure:
- Retention rate (percent of scheduled study visits completed by each participant).
Measured: 7-Day post drug administration integration session, Visit #8
Participant retention rate
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant.
Measure:
- Retention rate (percent of scheduled study visits completed by each participant).
Measured: 30-days post drug administration follow-up (Follow-up #1), Visit #9
Participant retention rate
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant.
Measure:
- Retention rate (percent of scheduled study visits completed by each participant).
Measured: 60-days post drug administration follow-up (Follow-up #2), Visit #10
Participant retention rate
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant.
Measure:
- Retention rate (percent of scheduled study visits completed by each participant).
Measured: 120-days post drug administration follow-up (Follow-up #3), Visit #11 (Final visit)
Preliminary efficacy of psilocybin on methamphetamine abstinence
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures.
Measure:
- Urine drug screen results (positive/negative for methamphetamine).
Measured: Screening, Visit #1
Preliminary efficacy of psilocybin on methamphetamine abstinence
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures.
Measure:
- Urine drug screen results (positive/negative for methamphetamine).
Measured: Day of drug administration, Visit #6 (on study day 0)
Preliminary efficacy of psilocybin on methamphetamine abstinence
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures.
Measure:
- Urine drug screen results (positive/negative for methamphetamine).
Measured: 120 days post drug administration (Follow up #3), Visit #11(final visit)
Preliminary efficacy of psilocybin on methamphetamine abstinence
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures.
Measure:
- Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days.
Measured: Screening, Visit #1
Preliminary efficacy of psilocybin on methamphetamine abstinence
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures.
Measure:
- Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days.
Measured: 30 day post drug administration (Follow up #1), Visit #9
Preliminary efficacy of psilocybin on methamphetamine abstinence
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures.
Measure:
- Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days.
Measured: 60 day post drug administration (Follow up #2), visit #10
Preliminary efficacy of psilocybin on methamphetamine abstinence
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures.
Measure:
- Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days.
Measured: 120 days post drug administration (Follow up #3), visit #11
Mystical experiences associated with psilocybin administration
Description: The subjective effects of psilocybin will be assessed using validated self-report questionnaires.
Measure:
- Mystical Experience Questionnaire (MEQ-30): Total score range = 0-150; higher scores indicate a more intense mystical experience.
Measured: Day of drug administration, Visit #6 (on study day 0)
Challenging experiences associated with psilocybin administration
Description: The subjective effects of psilocybin will be assessed using validated self-report questionnaires.
Measure:
- Challenging Experience Questionnaire (CEQ): Total score range = 0-200; higher scores indicate a more challenging experience.
Measured: Day of drug administration, Visit #6 (on study day 0)
Physiological responses to psilocybin administration
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration.
Measure:
- Heart rate (beats per minute).
Measured: Baseline - Visit #2
Physiological responses to psilocybin administration
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration.
Measure:
- Heart rate (beats per minute).
Measured: Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing)
Physiological responses to psilocybin administration
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration.
Measure:
- Heart rate (beats per minute).
Measured: Day of drug administration(hourly) - Visit #6 (on study day 0)
Physiological responses to psilocybin administration
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration.
Measure:
- Heart rate (beats per minute).
Measured: Post-session monitoring day of drug administration - Visit #6 (on study day 0)
Physiological responses to psilocybin administration
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration.
Measure:
- Blood pressure (systolic/diastolic, mmHg).
Measured: Baseline - Visit #2
Physiological responses to psilocybin administration
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration.
Measure:
- Blood pressure (systolic/diastolic, mmHg).
Measured: Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing)
Physiological responses to psilocybin administration
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration.
Measure:
- Blood pressure (systolic/diastolic, mmHg).
Measured: Day of drug administration(hourly) - Visit #6 (on study day 0)
Physiological responses to psilocybin administration
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration.
Measure:
- Blood pressure (systolic/diastolic, mmHg).
Measured: Post-session monitoring day of drug administration - Visit #6 (on study day 0)
Secondary outcomes (8)
Effects of psilocybin on quality of life
Description: Quality of life will be assessed using a validated self-report questionnaire.
Measure:
- Quality of Life Questionnaire (QOL): Score range = 14-70; higher scores indicate greater life satisfaction.
Measured: Baseline assessment, visit #2
Effects of psilocybin on quality of life
Description: Quality of life will be assessed using a validated self-report questionnaire.
Measure:
- Quality of Life Questionnaire (QOL): Score range = 14-70; higher scores indicate greater life satisfaction.
Measured: 30 day post drug administration (Follow up #1), Visit #9
Effects of psilocybin on quality of life
Description: Quality of life will be assessed using a validated self-report questionnaire.
Measure:
- Quality of Life Questionnaire (QOL): Score range = 14-70; higher scores indicate greater life satisfaction.
Measured: 60 day post drug administration (Follow up #2), Visit #10
Effects of psilocybin on quality of life
Description: Quality of life will be assessed using a validated self-report questionnaire.
Measure:
- Quality of Life Questionnaire (QOL): Score range = 14-70; higher scores indicate greater life satisfaction.
Measured: 120 days post drug administration (Follow up #3), Visit #11
Effects of psilocybin on negative affect
Description: Symptoms of depression, anxiety, and stress will be assessed using a validated self-report scale.
Measure:
- Depression Anxiety and Stress Scale (DASS-21): Score range = 0-126; higher scores indicate more severe negative affect.
Measured: Baseline assessment, Visit #2
Effects of psilocybin on negative affect
Description: Symptoms of depression, anxiety, and stress will be assessed using a validated self-report scale.
Measure:
- Depression Anxiety and Stress Scale (DASS-21): Score range = 0-126; higher scores indicate more severe negative affect.
Measured: 30 day post drug administration (Follow up #1), Visit #9
Effects of psilocybin on negative affect
Description: Symptoms of depression, anxiety, and stress will be assessed using a validated self-report scale.
Measure:
- Depression Anxiety and Stress Scale (DASS-21): Score range = 0-126; higher scores indicate more severe negative affect.
Measured: 60 day post drug administration (Follow up #2), visit #10
Effects of psilocybin on negative affect
Description: Symptoms of depression, anxiety, and stress will be assessed using a validated self-report scale.
Measure:
- Depression Anxiety and Stress Scale (DASS-21): Score range = 0-126; higher scores indicate more severe negative affect.
Measured: 120 days post drug administration (Follow up #3), Visit #11
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Mar 2025
- Study start4 Apr 2025
- Primary completionMar 2027 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Methamphetamine Use DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kevin Murnane
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Kevin Murnane, Louisiana State University Health Sciences Center Shreveport
- Investigators
- Kevin S Murnane, PhD, Principal investigator, Louisiana State University Health Science Center Shreveport
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06899594
- Sponsor's protocol ID
- STUDY00002094
- Status last verified
- Mar 2025
- First submitted
- 27 Nov 2024
- Last updated
- 7 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine
- ClinicalTrials.gov ID
- NCT06899594
- Acronym / sponsor ID
- STUDY00002094
- Conditions
- Methamphetamine Use Disorder
- Keywords
- Methamphetamine, Psilocybin, Psychedelics, Methamphetamine Use Disorder, Stimulant Use Disorder, Methamphetamine Addiction, Addiction, Substance Use Disorder
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Kevin MurnaneUniversity, hospital or other
- Study start
- 4 Apr 2025 (actual)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 28 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and tolerability as rates of retention and challenging experiences, among other factors.
Detailed description
This is an open-label pilot study evaluating the feasibility and tolerability of a single 25 mg psilocybin dose in promoting abstinence from methamphetamine. Participants will attend 10 to 12 study visits over a period of up to six months.
Participants will be recruited from a population receiving treatment for methamphetamine dependence at a local residential treatment facility. Recruitment will involve informative presentations to current clients and counselor-facilitated referrals based on provided inclusion criteria. Prescreening will utilize information collected by the treatment center during the client's admission process.
Individuals who meet prescreening criteria will be invited to an in-person screening visit, conducted after obtaining informed consent. The screening visit will include a clinical review, a detailed psychiatric interview, self-report questionnaires, a comprehensive medical history, and safety laboratory testing, including blood draws.
Once eligibility is confirmed, participants will proceed with study enrollment and complete baseline assessments, which will measure substance use, quality of life, and executive function. Three preparatory sessions will follow over a two-week period to establish trust and rapport between participants and session monitors, educate participants on the study protocol, and prepare them for the psilocybin session. Two preparatory sessions may be conducted via telehealth to enhance feasibility, while the third will be conducted in person with both the primary and secondary monitors present. A medical examination will be performed within the week preceding psilocybin administration.
Within a week of the third preparatory session, participants will attend a psilocybin administration session. Participants will arrive at the study location by 9:30 AM and undergo safety screenings, including breathalyzer testing, before psilocybin administration at approximately 10:00 AM. Participants will have been instructed to consume a low-fat breakfast prior to arrival. During the session, cardiovascular measures (e.g., heart rate, blood pressure) will be monitored upon arrival, hourly throughout the session, and as clinically indicated.
The psilocybin session, lasting approximately 6-8 hours, will be monitored by both the primary and secondary session monitors, ensuring that at least one individual is present with the participant at all times. At the conclusion of the session, participants will complete questionnaires assessing their subjective experiences. Participants will then be released into the care of treatment center staff, who will provide emotional support. Participants will also receive contact information for the primary monitor to access support if needed.
Post-session integration will include two telehealth sessions: the first within one day of the psilocybin session and the second approximately 7 days later (±3 days). These sessions will provide opportunities to discuss insights or challenges arising from the psilocybin experience, with an emphasis on promoting adaptive cognitive and behavioral changes.
Follow-up assessments will occur via telehealth at 30 and 60 days post-psilocybin, with an in-person assessment conducted at 120 days. The final visit will include a urine drug screen.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Psilocybin | Experimental | Drug: Psilocybin 25 mgParticipants will be administered 25mg of Psilocybin. |
Who may qualify
- Ages
- 25 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Age 25-65 at time of signing informed consent
- Identification of methamphetamine as drug of choice
- Score of at least 3 on the Severity of Dependence Scale
- Have been at the designated local treatment facility for at least 7 days
- Use of methamphetamine in the month preceding admission to the treatment center
Key exclusion criteria (33 listed)
- Meeting criteria for substance dependence diagnoses other than methamphetamine (except nicotine and cannabis) as assessed by the MINI
- History of Hallucinogen Use Disorder or Hallucinogen Persisting Perceptive Disorder
- Women who are pregnant, plan to become pregnant, or are breast feeding
- Women who do not agree to engage in abstinence or are not using dual contraceptive methods at the time of enrollment and for the study duration
- Current hypertension (exceeding 140 systolic and 90 diastolic at resting as described below) at screening or during vitals taken pre-dosing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Psilocybin 25 mg25 mg administered orally (capsules) | Drug | Psilocybin |
Primary outcome
Participant retention rate
Time frame: Screening, Visit #1
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant).
Participant retention rate
Time frame: Baseline Assessments, Visit #2
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant).
Participant retention rate
Time frame: Preparatory Session #1, Visit #3 (on study day (-)14; 14 days prior to dosing)
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant).
Participant retention rate
Time frame: Preparatory Session #2, Visit #4 (on study day (-) 7; 7 days prior to dosing)
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant).
Participant retention rate
Time frame: Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing)
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant).
Participant retention rate
Time frame: Day of drug administration, Visit #6 (on study day 0)
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant).
Participant retention rate
Time frame: 1-Day post drug administration integration session, Visit #7
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant).
Participant retention rate
Time frame: 7-Day post drug administration integration session, Visit #8
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant).
Participant retention rate
Time frame: 30-days post drug administration follow-up (Follow-up #1), Visit #9
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant).
Participant retention rate
Time frame: 60-days post drug administration follow-up (Follow-up #2), Visit #10
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant).
Participant retention rate
Time frame: 120-days post drug administration follow-up (Follow-up #3), Visit #11 (Final visit)
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant).
Preliminary efficacy of psilocybin on methamphetamine abstinence
Time frame: Screening, Visit #1
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Urine drug screen results (positive/negative for methamphetamine).
Preliminary efficacy of psilocybin on methamphetamine abstinence
Time frame: Day of drug administration, Visit #6 (on study day 0)
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Urine drug screen results (positive/negative for methamphetamine).
Preliminary efficacy of psilocybin on methamphetamine abstinence
Time frame: 120 days post drug administration (Follow up #3), Visit #11(final visit)
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Urine drug screen results (positive/negative for methamphetamine).
Preliminary efficacy of psilocybin on methamphetamine abstinence
Time frame: Screening, Visit #1
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days.
Preliminary efficacy of psilocybin on methamphetamine abstinence
Time frame: 30 day post drug administration (Follow up #1), Visit #9
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days.
Preliminary efficacy of psilocybin on methamphetamine abstinence
Time frame: 60 day post drug administration (Follow up #2), visit #10
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days.
Preliminary efficacy of psilocybin on methamphetamine abstinence
Time frame: 120 days post drug administration (Follow up #3), visit #11
Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days.
Mystical experiences associated with psilocybin administration
Time frame: Day of drug administration, Visit #6 (on study day 0)
Description: The subjective effects of psilocybin will be assessed using validated self-report questionnaires. Measure: * Mystical Experience Questionnaire (MEQ-30): Total score range = 0-150; higher scores indicate a more intense mystical experience.
Challenging experiences associated with psilocybin administration
Time frame: Day of drug administration, Visit #6 (on study day 0)
Description: The subjective effects of psilocybin will be assessed using validated self-report questionnaires. Measure: * Challenging Experience Questionnaire (CEQ): Total score range = 0-200; higher scores indicate a more challenging experience.
Physiological responses to psilocybin administration
Time frame: Baseline - Visit #2
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: * Heart rate (beats per minute).
Physiological responses to psilocybin administration
Time frame: Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing)
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: * Heart rate (beats per minute).
Physiological responses to psilocybin administration
Time frame: Day of drug administration(hourly) - Visit #6 (on study day 0)
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: * Heart rate (beats per minute).
Physiological responses to psilocybin administration
Time frame: Post-session monitoring day of drug administration - Visit #6 (on study day 0)
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: * Heart rate (beats per minute).
Physiological responses to psilocybin administration
Time frame: Baseline - Visit #2
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: * Blood pressure (systolic/diastolic, mmHg).
Physiological responses to psilocybin administration
Time frame: Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing)
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: * Blood pressure (systolic/diastolic, mmHg).
Physiological responses to psilocybin administration
Time frame: Day of drug administration(hourly) - Visit #6 (on study day 0)
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: * Blood pressure (systolic/diastolic, mmHg).
Physiological responses to psilocybin administration
Time frame: Post-session monitoring day of drug administration - Visit #6 (on study day 0)
Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: * Blood pressure (systolic/diastolic, mmHg).
8 secondary outcomes
Effects of psilocybin on quality of life
Time frame: Baseline assessment, visit #2
Effects of psilocybin on quality of life
Time frame: 30 day post drug administration (Follow up #1), Visit #9
Effects of psilocybin on quality of life
Time frame: 60 day post drug administration (Follow up #2), Visit #10
Effects of psilocybin on quality of life
Time frame: 120 days post drug administration (Follow up #3), Visit #11
Effects of psilocybin on negative affect
Time frame: Baseline assessment, Visit #2
Effects of psilocybin on negative affect
Time frame: 30 day post drug administration (Follow up #1), Visit #9
Effects of psilocybin on negative affect
Time frame: 60 day post drug administration (Follow up #2), visit #10
Effects of psilocybin on negative affect
Time frame: 120 days post drug administration (Follow up #3), Visit #11
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2025.
- Individual participant dataSharing planned: No
Related trials for Methamphetamine Use Disorder
Active, not recruiting
Closed-loop TBS Targeting rPO for the Core Clinical Features of Methamphetamine Use Disorder
Methamphetamine Use Disorder, Substance Use Disorder
RecruitingPhase 2
Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder
Methamphetamine Use Disorder
Recruiting
Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement
Methamphetamine Use, Heart Failure
RecruitingPhase 2
A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine
Methamphetamine Intoxication, Methamphetamine Disorders
Active, not recruiting
The Human Stress Response in a Simulated ED Setting
Stress Physiology, Stress Reaction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kevin S Murnane, PhD principal investigator
Louisiana State University Health Science Center Shreveport
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Psilocybin 25 mg in people with Methamphetamine Use Disorder, run by Kevin Murnane at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 33 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kevin S Murnane, PhD ((318) 675-7830, kevin.murnane@lsuhs.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Participant retention rate (time frame: Screening, Visit #1). The study lists 28 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2025.